February 11, 2021 09:00 AM ESTUpdated February 12, 11:57 PM

All in on ide-cel, Bristol Myers Squibb writes off $470M as second BCMA CAR-T is ejected from the pipeline

With just a little over a month to go before the FDA is slated to decide on ide-cel, Bristol Myers Squibb is

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

All in on ide-cel, Bris­tol My­ers Squibb writes off $470M as sec­ond BC­MA CAR-T is eject­ed from the pipeline